Effect of age on response to rivastigmine or donepezil in patients with Alzheimer's disease

References

• Bowler JV, Munoz DG, Merskev H, Hachinski V. Factors affecting the age of onset and rate of progression of Alzheimer’s disease. J Neurol Neurosurg Psychiatry 1998;65:184–90
   PubMed Web of Science ®Google Scholar
• Hansen LA, DeTeresa R, Tobias H, Alford M, Terry RD. Neocortical morphometry, lesion counts, and choline acetyltransferase levels in the age spectrum of Alzheimer’s disease. Neurology 1988;38:48–54
   Google Scholar
• Mann DMA. Pathological correlates of dementia in Alzheimer’s disease. Neurobiol Aging 1994;15:357–60
   PubMed Web of Science ®Google Scholar
• Neuropathology Group. Medical Research Council Cognitive Function and Aging Study. Pathological correlates of late-onset dementia in a multicentre, community-based population in England and Wales. Lancet 2001;357:169–75
   Google Scholar
• Schoenmaker N, Van Gool WA. The age gap between patients in clinical studies and in the general population: a pitfall for dementia research. Lancet Neurol 2004;3:627–30
   PubMed Web of Science ®Google Scholar
• Van Gool WA, Eikelenboom P. The two faces of Alzheimer’s disease. J Neurol 2000;247:500–5
   PubMed Web of Science ®Google Scholar
• Rosser MN, Iverson LL, Reynolds GP, Mountjoy CQ, Roth M. Neurochemical characteristics of early and late onset types of Alzheimer’s disease. Br Med J (Clin Res Ed) 1984;288: 961–4
   PubMed Web of Science ®Google Scholar
• Ho GJ, Hansen LA, Alford MF, et al. Age at onset is associated with disease severity in Lewy body variant and Alzheimer’s disease. Neuroreport 2002;13:1825–8
   PubMed Web of Science ®Google Scholar
• Jacobs D, Sano M, Marder K, et al. Age at onset of Alzheimer’s disease: relation to pattern of cognitive dysfunction and rate of decline. Neurology 1994;44:1215–20
   PubMed Web of Science ®Google Scholar
• Farrer LA, Cupples LA, Haines JL, et al. Effects of age, sex and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease: a meta-analysis. J Am Med Assoc 1997;278:1349–56
   PubMed Web of Science ®Google Scholar
• Silverman JM, Ciresi G, Smith CJ, Marin DB, Schnaider-Beeri M. Variability of familial risk of Alzheimer’s disease across the late life span. Arch Gen Psychiatry 2005;62:565–73
   Google Scholar
• Kukull WA. Larson EB, Reifler BV, Lampe TH, Yerby MS, Hughes JP. The validity of 3 clinical diagnostic criteria for Alzheimer’s disease. Neurology 1990;40:1364–9
   PubMed Web of Science ®Google Scholar
• Bullock RA, Touchon J, Bergman H, et al. Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer’s disease over 2 years. Curr Med Res Opin 2005;21:1317–27
   PubMed Web of Science ®Google Scholar
• Huang W, Qiu C, von Strauss E, Winblad B, Fratiglioni L. APOE genotype, family history of dementia, and Alzheimer disease risk: a 6-year follow-up study. Arch Neurol 2004;61: 1930–4
   Google Scholar
• Payami H, Crimslid H, Oken B, et al. A prospective study of cognitive health in the elderly (Oregon Brain Aging Study): effects of family history and apolipoprotein E genotype. Am J Hum Genet 1997;60:948–56
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association. Diagnostic and statistical manual of mental Disorders, 4th edn. Washington (DC): American Psychiatric Association; 1994
   Google Scholar
• McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 1984;34:939–44
   PubMed Web of Science ®Google Scholar
• Folstein MF, Folstein SE, McHugh PR. ‘Mini-Mental State’: a practical method for grading the cognitive state of patients for the clinician. J Psychiatric Res 1975;12:189–98
   Google Scholar
• Panisset M, Roudier M, Saxton J, Boller F. Severe impairment battery. A neurological test for severely demented patients. Arch Neurol 1994;51:41–5
   PubMed Web of Science ®Google Scholar
• Reisberg B, Ferris SH, de Leon MJ, Crook T. The global deterioration scale for assessment of primary degenerative dementia. Am J Psychiatry 1982;139:1136–9
   PubMed Web of Science ®Google Scholar
• Galasko D, Bennett D, Sano M, et al. An inventory to assess activities of daily living for clinical trials in Alzheimer’s disease [The Alzheimer’s Disease Cooperative Study]. Alzheimer Dis Assoc Disord 1997;11(Suppl 2):533–9
   Google Scholar
• Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The neuropsychiatric inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994;44:2308–14
   Google Scholar
• Kaufer DI, Cummings JL, Christine D, et al. Assessing the impact of neuropsychiatric symptoms in Alzheimer’s disease: the Neuropsychiatric Inventory Caregiver Distress Scale. J Am Geriatr Soc 1998;46:210–5
   PubMed Web of Science ®Google Scholar
• Cummings JL, Nadel A, Masterman D, Cyprus PA. Efficacy of metrifonate in improving the psychiatric and behavioral disturbances of patients with Alzheimer’s disease. J Geriatr Psychiatry Neurol 2001;14:101–8
   PubMed Web of Science ®Google Scholar
• Grossberg GT. Cholinesterase inhibitors for the treatment of Alzheimer’s disease: getting on and staying on. Curr Ther Res 2003;64:216–35
   PubMed Web of Science ®Google Scholar
• Data on file, Novartis pharmaceuticals
   Google Scholar
• Weinstock M. Selectivity of cholinesterase inhibition. Clinical implications for the treatment of Alzheimer’s Disease. CNS Drugs 1999;12:307–23
   Google Scholar
• Mesulam M, Guillozet A, Shaw P, Quinn B. Widely spread butyrylcholinesterase can hydrolyze acetylcholine in the normal and Alzheimer brain. Neurobiol Dis 2002;9:88–93
   PubMed Web of Science ®Google Scholar
• Perry E, McKeith I, Ballard C. Butyrylcholinesterase and progression of cognitive deficits in dementia with Lewy bodies. Neurology 2003;60:1852–3
   Google Scholar
• Holmes C, Ballard C, Lehman D, et al. Rate of progression of cognitive decline in Alzheimer’s disease: effect of butyrylcholinesterase K gene variation. J Neurol Neurosurg Psychiatry 2005;76:640–3
   PubMed Web of Science ®Google Scholar
• O’Brien KK, Saxby BK, Ballard CG, et al. Regulation of attention and response to therapy in dementia by butyrylcholinesterase. Pharmacogenetics 2003;13:231–9
   Google Scholar
• Bartels CF, Jensen FS, Lockridge O, et al. DNA mutation associated with the human butyrylcholinesterase K-variant and its linkage to the atypical variant mutation and other polymorphic sites. Am J Hum Genet 1992;50:1086–103
   PubMed Web of Science ®Google Scholar
• Altamirano CV, Bartels CF, Lockridge O. The butyrylcholinesterase K-variant shows similar cellular protein turnover and quaternary interaction to the wild-type enzyme. J Neurochem 2000;74:869–77
   Google Scholar
• Blesa R, Bullock R, He Y, et al. Effect of BuChE genotype on response to rivastigmine or donepezil in younger patients with Alzheimer’s disease [in preparation]
   Google Scholar